Skip to main content

Patients Face High Out-of-Pocket Costs After Incident Cancer Diagnosis

Medically reviewed by Carmen Pope, BPharm. Last updated on July 25, 2025.

via HealthDay

FRIDAY, July 25, 2025 -- Patients face high out-of-pocket costs (OOPCs) after an incident diagnosis of cancer, with costs increasing with stage of diagnosis, according to a study published online July 21 in JAMA Network Open.

Liam Rose, Ph.D., from the Stanford University School of Medicine in Palo Alto, California, and colleagues conducted a retrospective cohort study to examine OOPCs attributable to initial treatment of common cancers (breast, colorectal, and lung) among privately insured individuals diagnosed at different stages. The cohort included 46,158 patients younger than 65 years, including 19,656 with cancer and 26,502 without cancer (control group). Of those with cancer, 14,581; 2,842; and 2,233 patients had breast, colorectal, and lung cancer, respectively.

The researchers found that an incident cancer diagnosis was associated with a $592.53 per month mean increase in OOPCs for six months after diagnosis. There was a monotonic increase in cost with stage at diagnosis (mean OOPC increase ranged from $462.01 to $719.97 per month for stage 0 and 4, respectively).

"The variability in OOPCs based on cancer stage underscores the need for policies such as paid sick leave, that address both insurance continuity and financial assistance, especially for patients with more advanced cancer," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Features of Immunesenescence Present in Early Stages of Rheumatoid Arthritis

THURSDAY, Sept. 11, 2025 -- Some features of immunesenescence are present in the very early stages of rheumatoid arthritis (RA), according to a study published online Sept. 3 in...

Urine Biomarker Panel Sensitive, Specific for Prostate Cancer Diagnosis

THURSDAY, Sept. 11, 2025 -- A urine-based biomarker panel has high accuracy for diagnosing prostate cancer (PCa), according to a study published in the September issue of...

Hospitals Vary in Their Definition of Blood Culture Contamination

THURSDAY, Sept. 11, 2025 -- U.S. hospitals vary in how they define blood culture contamination (BCC), according to a study published online July 11 in the Journal of Clinical...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.